HMGB1 Release From Hemorrhagic Shock Patients

It is reported that high mobility group box 1 (HMGB1), a non-histone nuclear protein, can serve as an alarmin with damage associated molecular patterns to activate immune responses in the early stages of hemorrhagic shock (HS). However, the origin of HMGB1 and how it is released following HS is poorly understood. In this study, we teased out this mechanism. We try to record the concentration of serum HMGB1 protein following HS in clinical patients.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Intensive Care Unit Adult Disease Disease Hemorrhage Hemorrhagic Shock Pathologic Processes Pathological Conditions, Signs and Symptoms Shock Shock, Hemorrhagic

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

The First Hospital of Chenzhou

Chenzhou, Hunan, 450003, China

About this study

The study was approved by the First People's Hospital of Chenzhou, Hunan, P.R. China. Consent was obtained from patients in their hospital course. Eighteen patients were enrolled for each group. In addition, Acute Physiological and Chronic Health Evaluation II (APACHE II) score was used to evaluate the severity and morbidity of HS patients Serial blood samples were collected at indicated time points on hospital admission for HS patients (0, 2, 4, 8, 24, and 72 h following HS). Levels of HMGB1 were detected by ELISA according to the kit manufacturer's instructions.

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Hemorrhagic shock (HS) was defined as out-of-hospital systolic blood pressure (SBP) of 70 mmHg or less or SBP ranging 71 to 90 mmHg with a heart rate of 108 beats/min or more.

Exclusion criteria

pregnancy, <18 years old, more than 2,000 mL of intravenous fluids or blood before enrollment, hypothermia, drowning, asphyxia, burns, isolated penetrating head injury, time of call received by dispatch to study intervention longer than 4 h, known prisoners, and transfer from another hospital

Treatment and study plan

Primary outcomes

serum HMGB1 concentration

Time frame: 24 hours following hemorrhagic shock

the concentration of serum HMGB1 were progressively increased following Hemorrhagic shock

Sponsors and collaborators

Lead sponsor

Xingui Dai

Other

Registry information

Official study title

Evidence for SIRT1 Mediated HMGB1 Release From Kidney Cells in the Early Stages of Hemorrhagic Shock

Important dates

Study start: 2017
Primary completion: 2018
Study completion: 2018
First posted: May 24, 2018
Registry last updated: May 24, 2018

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed